Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Jun 15;10(12):1775-9.
doi: 10.3748/wjg.v10.i12.1775.

Inhibition of Fas/FasL mRNA expression and TNF-alpha release in concanavalin A-induced liver injury in mice by bicyclol

Affiliations

Inhibition of Fas/FasL mRNA expression and TNF-alpha release in concanavalin A-induced liver injury in mice by bicyclol

Min Li et al. World J Gastroenterol. .

Abstract

Aim: Bicyclol, 4, 4'-dimethoxy-5, 6, 5', 6'-dimethylene-dioxy-2-hydroxymethyl -2'-carbonyl biphenyl, is a new anti-hepatitis drug. The aim of the present study was to investigate the protective effect of bicyclol on concanavalin A (Con A)-induced immunological liver injury in mice and its mechanism.

Methods: Liver injury was induced by injection of Con A via tail vein of mice and assessed biochemically and histologically. Serum transaminase and tumor necrosis factor alpha (TNF-alpha) were determined. Liver lesions were observed by light microscope. Expressions of TNF-alpha, interferon gamma (IFN-gamma), Fas and Fas ligand (FasL) mRNA in the livers were measured by RT-PCR.

Results: Serum transaminase level and liver lesions in Con A-induced mice were markedly reduced by oral administration of 100, 200 mg/kg of bicyclol. TNF-alpha level in serum was also reduced by bicyclol. Con A injection induced up-regulation of TNF-alpha, IFN-gamma, Fas and FasL mRNA expression in liver tissues. Bicyclol significantly down-regulated the expression of IFN-gamma, Fas and FasL mRNA, but only slightly affected TNF-alpha mRNA expression in liver tissues.

Conclusion: Bicyclol protects against Con A-induced liver injury mainly through inhibition of Fas/FasL mRNA expression in liver tissues and TNF-alpha release in mice.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical structure of bicyclol.
Figure 2
Figure 2
Time-course of Con A-induced liver serum ALT el-evation in mice. bP < 0.01 vs other time.
Figure 3
Figure 3
Light micrographs of livers from mice treated with Con A alone or in combination with bicyclol. Original magnification×200. A: normal control mouse. B: Con A injected mouse; C, mouse treated with bicyclol 200 mg/kg.
Figure 4
Figure 4
Dynamic changes of serum TNF-α level after Con A injection in mice. Each point represents mean ± SD of six mice.
Figure 5
Figure 5
Lowering effect of bicyclol on the elevated serum TNF-α Level induced by Con A injection in mice. Each bar represents mean ± SD of 6 mice per group bP < 0.01 vs Con A alone.
Figure 6
Figure 6
Effect of bicyclol on Con A induced TNF-α, IFN-γ, Fas and FasL mRNA expression determined by RT-PCR. A: Pho-tograph of ethidium bromide-stained amplification products. Lane 1, molecular mass markers; lane 2 and lane 3, control liver; lane 4 and lane 5, liver 2 h after Con A administration alone; lane 6 and lane 7, liver 2 h after injection of Con A in combination with 200 mg/kg bicyclol. B: Relative band intensity of amplification products compared with Cu/Zn SOD mRNA. Data represent the mean of two lanes. Each lane corresponds to the pooled livers from two mice. aP < 0.05 vs Con A alone.

Similar articles

Cited by

References

    1. Liu J, McIntosh H, Lin H. Chinese medicinal herbs for chronic hepatitis B: a systematic review. Liver. 2001;21:280–286. - PubMed
    1. Haria M, Benfield P. Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Drugs. 1995;50:873–896. - PubMed
    1. Heathcote J. Treatment of HBe antigen-positive chronic hepatitis B. Semin Liver Dis. 2003;23:69–80. - PubMed
    1. Liu GT. The anti-virus and hepatoprotective effect of bicyclol and its mechanism of action. Chin J New Drug Clin. 2001;10:325–327.
    1. Yao GB, Ji YY, Wang QH, Zhou XQ, Xu DZ, Chen XY. A ran-domized double-blind controlled trial of bicyclol in treatment of chronic hepatitis B. Chin J New Drug Clin. 2002;21:457–461.

Publication types

MeSH terms